+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PARP Inhibitors Drug Therapy Market by Indication (Breast Cancer, Ovarian Cancer, Pancreatic Cancer), Drug (Niraparib, Olaparib, Rucaparib), Line Of Therapy, Treatment Setting, End User, Distribution Channel, Therapy Type, Patient Age Group - Global Forecast 2025-2030- Product Image
PARP Inhibitors Drug Therapy Market by Indication (Breast Cancer, Ovarian Cancer, Pancreatic Cancer), Drug (Niraparib, Olaparib, Rucaparib), Line Of Therapy, Treatment Setting, End User, Distribution Channel, Therapy Type, Patient Age Group - Global Forecast 2025-2030- Product Image
Sale

PARP Inhibitors Drug Therapy Market by Indication (Breast Cancer, Ovarian Cancer, Pancreatic Cancer), Drug (Niraparib, Olaparib, Rucaparib), Line Of Therapy, Treatment Setting, End User, Distribution Channel, Therapy Type, Patient Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674431
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The PARP inhibitors drug therapy market is experiencing strong momentum, driven by expanding clinical indications, evolving regulatory policies, and collaborative ecosystem strategies across oncology. Senior decision-makers are focusing on sustainable growth, resilient supply chains, and targeted clinical development as the competitive landscape matures rapidly.

Market Snapshot: PARP Inhibitors Drug Therapy Market Overview

The PARP inhibitors drug therapy market grew from USD 7.32 billion in 2024 to USD 8.01 billion in 2025, sustaining a compound annual growth rate of 9.24%. By 2030, the sector is expected to reach USD 12.44 billion, reflecting rising demand for targeted treatment protocols and strategic pipeline expansion.

Scope & Segmentation: Strategic Dimensions of the PARP Inhibitors Market

  • Indication: Breast cancer (hormone receptor positive, triple negative), ovarian cancer (by biomarker status: BRCA mutated, HRD, non-HRD), pancreatic cancer (advanced, early stage), and prostate cancer (metastatic, non-metastatic).
  • Drug Type: Niraparib, olaparib, rucaparib, talazoparib.
  • Line of Therapy: First line, maintenance, subsequent line.
  • Treatment Setting: Inpatient, outpatient.
  • End User: Hospitals, retail pharmacies, specialty clinics.
  • Distribution Channel: Hospital pharmacies, online pharmacies, retail pharmacies.
  • Therapy Type: Combination therapy, monotherapy.
  • Patient Age Group: Adults, elderly.
  • Geographical Coverage: Americas (including the United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (key markets such as United Kingdom, Germany, France, Russia, and more), and Asia-Pacific (including China, India, Japan, Australia, South Korea, among others).
  • Key Companies: AstraZeneca plc, GlaxoSmithKline plc, Clovis Oncology, Inc., Pfizer Inc., Merck & Co., Inc.

Key Takeaways: Strategic Insights for Decision-Makers

  • PARP inhibitors are reshaping cancer care with precision medicine, particularly benefiting patient populations with DNA repair deficiencies and complex biomarker profiles.
  • Collaborations between pharmaceutical companies and diagnostic developers are optimizing patient selection, which helps increase therapeutic impact and reduce off-target responses.
  • Combination therapies are gaining traction in clinical research, with focus on advancing efficacy and patient-centric treatment outcomes in both first-line and maintenance settings.
  • Increased global harmonization of regulatory processes and reimbursement policies is accelerating market entry and access, especially where government support aligns payer incentives with clinical outcomes.
  • Shifting attention to underserved regional markets and expansion into elderly patient cohorts drives further market differentiation and stakeholder value.

Impact of 2025 United States Tariff Policies

  • New US tariffs in 2025 added complexity to raw material procurement for both active pharmaceutical ingredients and diagnostic reagents.
  • Manufacturers are resolving cost challenges by near-shoring facilities and strengthening domestic partnerships, balancing operational investments with improved supply chain resilience.
  • Adaptive strategies around outcomes-based contracting and diversified sourcing are instrumental in maintaining patient access and fortifying market positioning amid shifting tariff landscapes.

Methodology & Data Sources

This strategic analysis utilizes both primary and secondary research approaches. Secondary research includes comprehensive reviews of scientific literature, clinical trials, and regulatory filings, while structured interviews with key opinion leaders, oncologists, and payers validate market assumptions and qualitative insights. Data triangulation and expert consultations ensure robust, actionable market intelligence.

Why This Report Matters

  • Supports evidence-based decision making for investment, clinical development, and go-to-market strategy within the competitive PARP inhibitors landscape.
  • Provides clarity on how shifting regulatory, tariff, and supply chain drivers affect strategic planning, market access, and long-term growth opportunities.
  • Enables stakeholders to benchmark corporate strategies, access market intelligence, and guide resource allocation across crucial clinical and commercial segments.

Conclusion

The report provides strategic insights to navigate the evolving PARP inhibitor market, emphasizing clinical innovation, adaptive business models, and robust supply chain management. It equips leaders to prioritize opportunities and drive measurable impact across the oncology value chain.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Clinical uptake of next generation oral PARP inhibitors with improved safety and tolerability profiles
5.2. Breakthrough regulatory approvals of PARP inhibitors for non-BRCA mutant indications expanding patient access
5.3. Strategic partnerships driving development of PARP inhibitor antibody drug conjugates for enhanced tumor targeting
5.4. Identification of novel predictive biomarkers to optimize PARP inhibitor patient selection and therapeutic outcomes
5.5. Emerging mechanisms of resistance to PARP inhibitors spurring innovation in second line combination strategies
5.6. Real world evidence highlighting long term cost effectiveness and quality of life benefits of maintenance PARP inhibitor use in ovarian cancer
5.7. Pipeline development of long acting injectable PARP inhibitors aimed at improving adherence and reducing dosing frequency
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. PARP Inhibitors Drug Therapy Market, by Indication
8.1. Introduction
8.2. Breast Cancer
8.2.1. Receptor Type
8.2.1.1. Hormone Receptor Positive
8.2.1.2. Triple Negative
8.3. Ovarian Cancer
8.3.1. Biomarker Status
8.3.1.1. Brca Mutated
8.3.1.2. Hrd
8.3.1.3. Non-Hrd
8.4. Pancreatic Cancer
8.4.1. Stage
8.4.1.1. Advanced
8.4.1.2. Early Stage
8.5. Prostate Cancer
8.5.1. Stage
8.5.1.1. Metastatic
8.5.1.2. Non-Metastatic
9. PARP Inhibitors Drug Therapy Market, by Drug
9.1. Introduction
9.2. Niraparib
9.3. Olaparib
9.4. Rucaparib
9.5. Talazoparib
10. PARP Inhibitors Drug Therapy Market, by Line Of Therapy
10.1. Introduction
10.2. First Line
10.3. Maintenance
10.4. Subsequent Line
11. PARP Inhibitors Drug Therapy Market, by Treatment Setting
11.1. Introduction
11.2. Inpatient
11.3. Outpatient
12. PARP Inhibitors Drug Therapy Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Retail Pharmacies
12.4. Specialty Clinics
13. PARP Inhibitors Drug Therapy Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. PARP Inhibitors Drug Therapy Market, by Therapy Type
14.1. Introduction
14.2. Combination Therapy
14.3. Monotherapy
15. PARP Inhibitors Drug Therapy Market, by Patient Age Group
15.1. Introduction
15.2. Adults
15.3. Elderly
16. Americas PARP Inhibitors Drug Therapy Market
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. Argentina
17. Europe, Middle East & Africa PARP Inhibitors Drug Therapy Market
17.1. Introduction
17.2. United Kingdom
17.3. Germany
17.4. France
17.5. Russia
17.6. Italy
17.7. Spain
17.8. United Arab Emirates
17.9. Saudi Arabia
17.10. South Africa
17.11. Denmark
17.12. Netherlands
17.13. Qatar
17.14. Finland
17.15. Sweden
17.16. Nigeria
17.17. Egypt
17.18. Turkey
17.19. Israel
17.20. Norway
17.21. Poland
17.22. Switzerland
18. Asia-Pacific PARP Inhibitors Drug Therapy Market
18.1. Introduction
18.2. China
18.3. India
18.4. Japan
18.5. Australia
18.6. South Korea
18.7. Indonesia
18.8. Thailand
18.9. Philippines
18.10. Malaysia
18.11. Singapore
18.12. Vietnam
18.13. Taiwan
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. AstraZeneca plc
19.3.2. GlaxoSmithKline plc
19.3.3. Clovis Oncology, Inc.
19.3.4. Pfizer Inc.
19.3.5. Merck & Co., Inc.
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. PARP INHIBITORS DRUG THERAPY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 20. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. PARP INHIBITORS DRUG THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. PARP INHIBITORS DRUG THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 31. PARP INHIBITORS DRUG THERAPY MARKET: RESEARCHAI
FIGURE 32. PARP INHIBITORS DRUG THERAPY MARKET: RESEARCHSTATISTICS
FIGURE 33. PARP INHIBITORS DRUG THERAPY MARKET: RESEARCHCONTACTS
FIGURE 34. PARP INHIBITORS DRUG THERAPY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PARP INHIBITORS DRUG THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HORMONE RECEPTOR POSITIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TRIPLE NEGATIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BRCA MUTATED, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BRCA MUTATED, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HRD, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HRD, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NON-HRD, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NON-HRD, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADVANCED, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADVANCED, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY EARLY STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY METASTATIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY METASTATIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NON-METASTATIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NON-METASTATIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY NIRAPARIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OLAPARIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RUCAPARIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TALAZOPARIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MAINTENANCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MAINTENANCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBSEQUENT LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SUBSEQUENT LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ADULTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ELDERLY, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY ELDERLY, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2025-2030 (USD MILLION)
TABLE 157. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2024 (USD MILLION)
TABLE 158. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 181. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 182. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 183. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 184. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 185. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2024 (USD MILLION)
TABLE 186. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2025-2030 (USD MILLION)
TABLE 187. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2024 (USD MILLION)
TABLE 188. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2025-2030 (USD MILLION)
TABLE 189. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2024 (USD MILLION)
TABLE 190. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2025-2030 (USD MILLION)
TABLE 191. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2024 (USD MILLION)
TABLE 192. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2025-2030 (USD MILLION)
TABLE 193. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 194. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 195. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 196. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 197. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 198. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 199. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
TABLE 200. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2025-2030 (USD MILLION)
TABLE 201. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 202. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 203. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 204. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 205. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 210. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 211. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 212. CANADA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 213. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 214. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 215. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 216. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 217. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2024 (USD MILLION)
TABLE 218. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2025-2030 (USD MILLION)
TABLE 219. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2024 (USD MILLION)
TABLE 220. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2025-2030 (USD MILLION)
TABLE 221. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2024 (USD MILLION)
TABLE 222. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2025-2030 (USD MILLION)
TABLE 223. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2024 (USD MILLION)
TABLE 224. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2025-2030 (USD MILLION)
TABLE 225. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 226. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 227. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 228. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 229. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 230. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 231. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
TABLE 232. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2025-2030 (USD MILLION)
TABLE 233. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 234. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 235. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 236. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 237. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 242. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 243. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 244. MEXICO PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 245. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 246. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 247. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 248. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 249. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2024 (USD MILLION)
TABLE 250. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2025-2030 (USD MILLION)
TABLE 251. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2024 (USD MILLION)
TABLE 252. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2025-2030 (USD MILLION)
TABLE 253. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2024 (USD MILLION)
TABLE 254. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2025-2030 (USD MILLION)
TABLE 255. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2024 (USD MILLION)
TABLE 256. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2025-2030 (USD MILLION)
TABLE 257. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 258. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 259. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 260. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 261. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 262. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 275. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 276. BRAZIL PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 277. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 278. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 279. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 280. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 281. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-2024 (USD MILLION)
TABLE 282. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2025-2030 (USD MILLION)
TABLE 283. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2018-2024 (USD MILLION)
TABLE 284. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY OVARIAN CANCER, 2025-2030 (USD MILLION)
TABLE 285. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2018-2024 (USD MILLION)
TABLE 286. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BIOMARKER STATUS, 2025-2030 (USD MILLION)
TABLE 287. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2018-2024 (USD MILLION)
TABLE 288. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PANCREATIC CANCER, 2025-2030 (USD MILLION)
TABLE 289. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 290. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 291. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2024 (USD MILLION)
TABLE 292. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PROSTATE CANCER, 2025-2030 (USD MILLION)
TABLE 293. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
TABLE 294. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY STAGE, 2025-2030 (USD MILLION)
TABLE 295. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2018-2024 (USD MILLION)
TABLE 296. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DRUG, 2025-2030 (USD MILLION)
TABLE 297. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 298. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 299. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
TABLE 300. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY TREATMENT SETTING, 2025-2030 (USD MILLION)
TABLE 301. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 306. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 307. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 308. ARGENTINA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 309. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 310. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 311. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 312. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 313. EUROPE, MIDDLE EAST & AFRICA PARP INHIBITORS DRUG THERAPY MARKET SIZE, BY RECEPTOR TYPE, 2018-

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this PARP Inhibitors Drug Therapy market report include:
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Clovis Oncology, Inc.
  • Pfizer Inc.
  • Merck & Co., Inc.

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 8.01 Billion
Forecasted Market Value ( USD ) by 2030 $ 12.44 Billion
Compound Annual Growth Rate9.2%
Regions CoveredGlobal
No. of Companies Mentioned6

Related Topics

Related Reports

Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2025 - Product Image

Poly ADP-Ribose Polymerase (PARP) Inhibitor Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Poly ADP-Ribose Polymerase (PARP) Inhibitors - Global Strategic Business Report - Product Image

Poly ADP-Ribose Polymerase (PARP) Inhibitors - Global Strategic Business Report

  • Report
  • 284 Pages
  • Global
From
Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025 - Product Image

Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
PARP Inhibitor Biomarkers Market by Product, by Service 1 & 2 Testing, by Application, by End-User, and By Region - Product Image

PARP Inhibitor Biomarkers Market by Product, by Service 1 & 2 Testing, by Application, by End-User, and By Region

  • Report
  • 200 Pages
  • Global
From
PARP Inhibitor Biomarkers - Global Strategic Business Report - Product Image

PARP Inhibitor Biomarkers - Global Strategic Business Report

  • Report
  • 278 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.